Dermata gets Australian patent acceptance for dermal filler delivery system
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- US and Iran discuss phased deal to reopen Hormuz and end US blockade, sources say
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
April 2, 2026 8:31 AM EDT- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -
- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis -
SAN DIEGO, CA / ACCESS Newswire / April 2, 2026 / Dermata Therapeutics, Inc. (Nasdaq: DRMA)(Nasdaq: DRMAW) ("Dermata" or the... More
